Nonsteroidal anti-inflammatory drugs: Cardiovascular, cerebrovascular and renal effects;Anti-inflamatórios não esteroides: Efeitos cardiovasculares, cérebro-vasculares e renais

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 4, 2010, Pages

  Batlouni, Michel ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

Anti inflammatory agents, non steroidal adverse effects; Physiological effects of drugs heart kidney cerebrum; Risk

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA PIROXICAM; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLADOL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC POTASSIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; LUMIRACOXIB; MELOXICAM; MOVATEC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PARECOXIB; PIROXICAM; PLACEBO; ROFECOXIB; SULINDAC; UNCLASSIFIED DRUG; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ARTHRITIS; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE SYSTEM ULCER; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DUODENUM ULCER; EDEMA; ENZYME INHIBITION; GASTRODUODENAL ULCER; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; NEPHROTIC SYNDROME; NONHUMAN; OSTEOARTHRITIS; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH PERFORATION; STOMACH ULCER; STROKE; THROMBOSIS; VASCULAR DISEASE; BRAIN; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; KIDNEY; RISK FACTOR; VASCULARIZATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE INHIBITORS; HUMANS; KIDNEY; RENAL INSUFFICIENCY; RISK FACTORS; STROKE;

EID: 77953149564     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Howard, Patricia A. Nonsteroidal anti-inflamatory drugs and cardiovascular Risk. J Am Coll Cardiol. 2004; 43: 519-525
2. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxigenas2 selectivity of widely used nosteroidal anti-inflammatory drugs. Am J Med. 1998; 104: 413-421 (Pubitemid 28274844)
3. Vane JR, Botting RM. Mechanism of action of nonsteroidal antinflammatory drugs. Am J Med. 1998; 104 (Suppl 3A): 2S-8S.
4. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005; 112: 759-770
5. Grosser T. Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inihibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116: 4-15. (Pubitemid 43121782)
6. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA. 1996; 93: 10417-10422
7. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984; 310:1065-1068. (Pubitemid 14131497)
8. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711
9. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflamatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115 (12):1634-1642 (Pubitemid 46648649)
10. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning conscious rabbits. Proc Natl Acad Sci USA. 2000; 97: 10197-10202
11. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, et al. Discovery of a new function of cyclooxigenase (COX-2): COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002; 55: 506-519
12. Fitzgerald GA, Austin YCS. COX-2 inihibitors and cardiovascular system Clin Exp Rheumatol. 2001;19 (Suppl 25): S31-6.
13. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345: 433-442
15. Abraham NS, El-Sereg HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Phamarcol Ther. 2007; 25: 913-924 (Pubitemid 46525353)
16. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use: a report of the American College of Cardiology Foundation task Force on Clinical Expert Consensus Documents. Circulation. 2008: 118; 1894-1909
17. Mkherjee D. Does a coxib-associated risk limit the clinical use of the compounds as analgesic anti-inflamatory drugs? Arguments in favor. Thromb Haemost. 2006; 96: 407-412 (Pubitemid 44560673)
18. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999; 106 (5B): 13S-24S.
19. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med. 1998; 319 (12): 761-767
20. Clive DM, Stroff JS. Renal syndromes associated with nonsteroid anti-inflammatory drugs. N Engl J Med. 1984; 310: 563-572
21. Whelton A. Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: Greenberg A. (ed.). Primer on kidney diseases. San Diego, CA: Academic Press; 1994. p. 163-167
22. Blum M, Aviram A. Ibuprofen-induced hyponatremia. Rheumatol Rehab. 1980; 19 (4): 258-259
23. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520-1528
24. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102
25. Cannon CP, Curtis SP, Bolognese JA, Laine L. MEDAL Steering Committee. Clinical trial design and pacients demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006; 152: 237-245 (Pubitemid 44109832)
26. Solomon SD, McMurray JJ, Pfeiffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080 (Pubitemid 40365348)
27. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. For the Celecoxib Long-Term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000; 284: 1247-1255
28. Kearney PM, Baigent C, Godwin J, Hall H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332: 1302-1308
29. Garcia Rodriguez LA, Tacconeli S, Pratignani P. Role of dose pontency in the prediction of risk of myocardial infarction associated with nosnteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008; 52: 1628-1636
30. McGettingan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic rewiew of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296 (13): 1633-1644 (Pubitemid 44511610)
31. Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event? J Am Coll Cardiol. 2008; 52: 1637-1639
32. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008; 371: 270-273
33. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993; 153: 477-484 (Pubitemid 23064991)
34. Jonhson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs on affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121 (4): 289-300.
35. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther. 1998; 20: 376-387
36. Andersonh F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nosteroidal anti-inflammatory drugs and the risk of ischemia. Stroke. 2006; 37 (7): 1725-1730
37. Haag Mendel DM, Michiel JB, Hofman A, Koudstaal PJ, Breteler Monique MB, Stricker Bruno HC. Cycloxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Inter Med. 2008; 168 (11): 1219-1224 (Pubitemid 351831405)
38. Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with incresead risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998; 158: 1108-1112 (Pubitemid 28242315)
39. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007; 23: 163-173 (Pubitemid 46201599)
40. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol. 2002; 29: 804-812